Mersana is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer. Leveraging decades of industry learnings, we have developed proprietary and highly differentiated ADC platforms and expertise to rapidly design and test novel ADCs and identify those with optimal efficacy, safety and tolerability. Using this strategy, we are building a robust pipeline of ADC candidates with the potential to make a life-changing difference for people living with cancer. Our lead candidate, upifitamab rilsodotin (UpRi), is a first-in-class Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a single-arm registration strategy, in patients with platinum-resistant ovarian cancer as well as the expansion portion of a Phase 1 proof-of-concept clinical study in patients with non-small cell lung cancer (NSCLC) adenocarcinoma.
Our experienced management team shares a strong commitment to scientific excellence and patient care, while also cultivating a highly collaborative and welcoming workplace. At Mersana, we have a passion for advancing therapies that make a significant impact in the lives of people living with cancer.
Mersana’s mission is to discover and develop life-changing antibody-drug conjugates for patients fighting cancer.
To create a world where all patients triumph over cancer.